Melisa Dirchwolf, Jennifer L. Dodge, Jane Gralla, Kiran M. Bambha, Trevor Nydam, Kenneth W. Hung, Hugo R. Rosen, Sandy Feng, Norah A. Terrault, Scott W. Biggins – 13 June 2015 – Donor age has become the dominant donor factor used to predict graft failure (GF) after liver transplantation (LT) in hepatitis C virus (HCV) recipients. The purpose of this study was to develop and validate a model of corrected donor age (CDA) for HCV LT recipients that transforms the risk of other donor factors into the scale of donor age.

Matteo Angelo Manini, Angelo Sangiovanni, Laura Martinetti, Davide Viganò, Vincenzo La Mura, Alessio Aghemo, Massimo Iavarone, Silvia Crespi, Antonio Nicolini, Massimo Colombo – 13 June 2015 – Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients.

Bulent Aydinli, Gurkan Ozturk, Sukru Arslan, Mecit Kantarci, Onder Tan, Ali Ahıskalioglu, Kemalettin Özden, Abdurrahim Colak – 13 June 2015 – Alveolar echinococcosis (AE) is a chronic disease caused by ingestion of the eggs of the parasitic cestode Echinococcosis multilocularis (EM). In severe cases, liver transplantation (LT) may represent the only possibility of survival and cure. Patients undergoing LT associated with hepatic AE at our institution between April 2011 and October 2014 were investigated retrospectively.

Roger F. Butterworth – 13 June 2015

Bashar A. Aqel, Surakit Pungpapong, Michael Leise, K. Tuesday Werner, Amy E. Chervenak, Kymberly D. Watt, Jennifer L. Murphy, Kristen Ryland, Andrew P. Keaveny, Ryan McLemore, Hugo E. Vargas – 11 June 2015 – Interferon (IFN)‐free regimens are needed to treat hepatitis C virus (HCV) infection. Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).

Lyna Zhang, Ajay Yesupriya, Man‐Huei Chang, Eyasu Teshale, Chong‐Gee Teo – 11 June 2015 – Hepatitis E viral (HEV) infection imposes a heavy health burden worldwide and is common in the United States. Previous investigations of risks addressed environmental and host behavioral/lifestyle factors, but host genetic factors have not been examined.

Carolina Jiménez Calvente, Alfica Sehgal, Yury Popov, Yong Ook Kim, Victor Zevallos, Ugur Sahin, Mustafa Diken, Detlef Schuppan – 10 June 2015 – Fibrosis accompanies the wound‐healing response to chronic liver injury and is characterized by excessive hepatic collagen accumulation dominated by collagen type I. Fibrosis often progresses to cirrhosis.

Kiran M. Bambha, Jennifer L. Dodge, Jane Gralla, David Sprague, Scott W. Biggins – 10 June 2015 – With increasing attention being paid to optimizing patient outcomes, it has been proposed that liver transplantation (LT) for individuals with elevated body mass index (BMI) values and high Model for End‐Stage Liver Disease (MELD) scores may adversely affect post‐LT outcomes. We investigated the impact of BMI on post‐LT outcomes in the context of MELD at LT.

Xu Yang, Xiao‐peng Tang, Yong‐hong Zhang, Kai‐zhong Luo, Yong‐fang Jiang, Hong‐yu Luo, Jian‐hua Lei, Wen‐long Wang, Ming‐ming Li, Han‐chun Chen, Shi‐lin Deng, Li‐ying Lai, Jun Liang, Min Zhang, Yi Tian, Yun Xu – 10 June 2015 – Hepatic copper determination is an important test for the diagnosis of Wilson's disease (WD). However, the method has not been standardized, the diagnostic accuracy has not been evaluated prospectively, and the optimal cut‐off value remains controversial.

Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot‐Matias, Veronica Miller – 10 June 2015 – Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.